Comparing Personalis (PSNL) & The Competition

Personalis (NASDAQ:PSNL) is one of 109 public companies in the “Life Sciences Tools & Services” industry, but how does it weigh in compared to its rivals? We will compare Personalis to similar companies based on the strength of its earnings, dividends, analyst recommendations, profitability, institutional ownership, risk and valuation.

Analyst Recommendations

This is a summary of current ratings and price targets for Personalis and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	1	7	3	0	2.18
Personalis Competitors	948	3168	5486	178	2.50

Personalis currently has a consensus target price of $14.54, suggesting a potential downside of 7.62%. As a group, “Life Sciences Tools & Services” companies have a potential downside of 1.96%. Given Personalis’ rivals stronger consensus rating and higher possible upside, analysts plainly believe Personalis has less favorable growth aspects than its rivals.

Profitability

This table compares Personalis and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Personalis	-153.84%	-46.47%	-35.30%
Personalis Competitors	-540.60%	-166.50%	-13.58%

Volatility and Risk

Personalis has a beta of 2.4, suggesting that its share price is 140% more volatile than the S&P 500. Comparatively, Personalis’ rivals have a beta of 1.15, suggesting that their average share price is 15% more volatile than the S&P 500.

Earnings & Valuation

This table compares Personalis and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Personalis	$69.67 million	-$81.27 million	-14.44
Personalis Competitors	$2.29 billion	$55.88 billion	-13.78

Personalis’ rivals have higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

61.9% of Personalis shares are owned by institutional investors. Comparatively, 53.7% of shares of all “Life Sciences Tools & Services” companies are owned by institutional investors. 4.2% of Personalis shares are owned by insiders. Comparatively, 15.0% of shares of all “Life Sciences Tools & Services” companies are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Personalis rivals beat Personalis on 9 of the 13 factors compared.

Personalis Company Profile

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.